His experience spans multiple areas, including tumor metabolism, novel targets discovery for cancer therapy, biomarker screening for clinical efficacy evaluation, small molecule and antibody-based PROTACs to target intracellular undruggable targets and assay platform development for different modalities such as ASO library construction for exon skipping, stapled-peptides library screening undruggable targets, as well as rare diseases in vitro and in vivo model selection and development. He has special interest in cancer immunotherapy and tumor relapse.
At Dewpoint, he has great interest in discovering novel immunotherapy drugs using condensate biology platform to develop novel treatments for tumor patients.
Design: SALIENCE Communication / Publiepress
Scientific animation: Visual Science